Novel Degrader Shows Anti–Lymphoma and Myeloma Activity December 19, 2024 The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer. Findings from a recent clinical trial ...

Research presented at the ASH Annual Meeting 2024 could change the treatment of patients with newly diagnosed multiple myeloma (MM ... of Fred Hutch Cancer Center in Seattle, who was not involved ...

"These results are a major advancement in the treatment of high-risk smoldering multiple myeloma," study leader Dr. S. Vincent Rajkumar of the Mayo Clinic Comprehensive Cancer Center in Rochester ...

I was 43 years old when this happened.” Then, 15 years ago, she was diagnosed with multiple myeloma — cancer of the blood. She was just 47 years old. “Nobody wants to hear the word that they ...

Google on Monday announced Willow, its latest, greatest quantum computing chip. The speed and reliability performance claims Google’s made about this chip were newsworthy in themselves, but what ...

This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression. Smoldering multiple myeloma is a condition in ...

Rutgers Cancer Institute of New Jersey, shares long-term follow-up data on the efficacy and safety of linvoseltamab in patients with heavily pretreated, relapsed/refractory (R/R) multiple myeloma.

We may get a commission if you buy through our links. Read our disclosure page to find out how can you help Windows Report sustain the editorial team. Read more The Microsoft Outlook top ribbon is ...